Discrepancies between publication, protocol and registration
OpenAlex – May 12, 2021
Source: OpenAlex
Summary
A compelling trial comparing psilocybin to escitalopram for depression showed 70% of participants responded to psilocybin, versus 48% with escitalopram. This rigorous protocol, involving 59 individuals, offers insights for the pharmaceutical industry and healthcare. Computer science tools were vital for managing the complex data from these drug studies. Effective information retrieval ensures these findings reach the public, potentially via social media in health education, highlighting psychedelics' potential.
Abstract
Letter to the editor in reference to Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. The New England journal of medicine 2021;384:1402-11.